Our Core

We aspire to make a lasting impact for patients with cardiac diseases

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Leadership Team

Prof. Dr. Dr. Thomas Thum
Prof. Thomas Thum
MD, PhD
Managing Director, CSO/CMO & Founder
Steffen Rump
Steffen Rump
PhD
VP Operations
Vicente Godoy
VP Quality Management & Compliance

Cardior Pharmaceuticals GmbH
Hollerithallee 20
30419 Hannover

Managing Director
Prof. Dr. Dr. Thomas Thum

Commercial Register
Registry Court: Hannover
HRB 214001
VAT ID: DE307067481

Email
info@cardior.de

Phone
+49 511 3385 9930

Contact us for career options
jobs@cardior.de

Visit us on
LinkedIn   X

Made with ❤︎ by Eatch
cardior signet white
Novo Nordisk logo
Effective 2 May 2024,
Cardior Pharmaceuticals is a wholly-owned subsidiary
of Novo Nordisk Region Europe A/S

This will close in 0 seconds

Prof. Thomas Thum

MD, PhD
Prof. Dr. Dr. Thomas Thum
Managing Director, CSO/CMO & Founder

Prof. Thomas Thum

MD, PhD

Prof. Dr. Dr. med. Thomas Thum, Founder and CSO of Cardior, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics and has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009, Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. Most recently he was appointed as Director of the neighboring Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. He has authored over 400 scientific publications in renowned and field-leading journals and has filed over 40 patents, nine of which have been successfully licensed to pharma companies and are currently in Phase 1/2 clinical development.

Steffen Rump

PhD
Steffen Rump
VP Operations

Steffen Rump

PhD

Dr. Steffen Rump is a seasoned professional in R&D with more than 10 years of experience and a track record in translational drug development of small molecules, ATMPs and vaccines in the biotechnological and pharmaceutical industry. His profound knowledge and experience in R&D operations includes planning, budgeting, and conducting of regulatory non-clinical and clinical development, CMC, quality management, and regulatory interactions in the EU and US along the pharmaceutical valuation chain from the early phases up to and including clinical Phase 2. He is inventor in PCT granted patents for therapeutics in oncology and cardiology. Steffen has been supporting Cardior’s assets since 2017 and guided the lead compound from non-clinical to successful clinical Phase 1b completion and beyond. Before he joined Cardior as VP operations, Steffen was the founder of SRConsulting, a service provider for product development, management and consultancy in the biotechnological and pharmaceutical industry based in Hannover, Germany. Steffen joined the industry after being postdoc at Harvard Medical School and was Project Manager and Consultant at Vakzine Projekt Management GmbH.

Vicente Godoy

VP Quality Management & Compliance

Vicente Godoy

Vicente Godoy, a trained pharmacist and biochemist, has held various quality-related positions in pharmaceutical industry. With over 15 years of professional experience he has worked in GxP-regulated environments in both Brazil and Germany. Having completed his Master of Science in Clinical Research at the University of Liverpool, UK in 2015, Vicente has concentrated his efforts on R&D Quality focusing on Good Clinical Practice (GCP) and Good Laboratory Practice (GLP). Vicente has conducted more than 150 audits across Europe, North America, Australia, and Brazil. His expertise extends to supporting regulatory inspections by agencies such as the FDA, PMDA, MHRA, and EMA. In March 2022 Vicente joined Cardior with a goal to implement a quality management system that ensures GCP-compliant activities on the clinical trial sponsor side. He also supports operational departments by overseeing clinical research activities at study sites and Clinical Research Organizations. Additionally, he plays a crucial role in implementing and maintaining Cardior’s compliance management system, ensuring adherence to legal and regulatory requirements, industry standards, and internal policies.